BioSpace News Archive

Short-Term Activist Harbert, With No Sector Experience and No Plan for Enzo, Seeks Fire Sale of Company at Depressed Prices

Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company today announced that the US Food and Drug Administration (FDA) has approved Enoxaparin Sodium Injection, USP, the generic equivalent of Lovenox®.

Zionexa, a radiopharmaceutical company specialized in the development and commercialization of in-vivo biomarkers for use in guiding targeted therapies in oncology, and PETNET Solutions Inc., a Siemens Healthineers company specializing in the manufacturing and distribution of positron emission tomography (PET) biomarkers, have entered into an exclusive agreement for the manufacturing and distribution of Zionexa’s new PET diagnostic drug, Fluoroestradiol

Aphios Corporation today announced that it was granted United States Patent No. 10,485,766 for the oral administration of Bryostatin-1 nanoparticles for the treatment of neurodegenerative diseases such as Huntington’s Disease, Parkinson’s disease, Multiple Sclerosis, Down syndrome and Alzheimer’s disease

BioTalent Canada launched a report, highlighting the positive effect Internationally Educated Professionals have had on the Canadian bio-economy.

NANOPEC, a leading provider of advanced materials next-gen bio-processing and healthcare products, today announced MetaFluorex™, a new class of ceramic films designed for in vitro diagnostics (IVD) kit enhancement that significantly improve their performance, cost of ownership, and enhance patient safety benefits.

Company also announces CRISPR Therapeutics CEO Samarth Kulkarni, Ph.D., Joins its Board of Directors

Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced that it will showcase the Company’s latest advancements to its medication management solution portfolio at this year’s American Society of Health-System Pharmacists 2019 Midyear Meeting, to be held in Las Vegas from December 7-11, 2019.

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that it has received positive efficacy data from preclinical studies of its Cymerus™ mesenchymal stem cells (MSCs) in a model of sepsis.

Graduates will provide much-needed hearing healthcare services throughout Africa